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Abstract
Background: Self-management may be an option to monitor oral anticoagulant therapy in health systems,
but before recommending it, we need to assess patients’ ability to take on this task. The purpose of the study
was to describe patients’ ability to self-manage and associated factors.
Methods: This was a 3-year prospective quasi-experimental study with a control group. Overall, 333 patients on
anticoagulant therapy from seven primary care health centres of the Basque Health Service were included in the
intervention group and followed up for 6 months after the intervention, assessing their ability to self-test and
self-manage. The intervention consisted of a patient training programme, providing detailed information on their
condition and its treatment, and practical training in how to use a portable blood coagulation monitor and adjust
their anticoagulant dose. Comparisons were made with a control group (333 patients receiving OAT under usual
care from the same seven health centres).
Outcome variables were ability to self-manage, quality of the outcome (in terms of time in therapeutic range),
and quality of life in the intervention group, and general patient characteristics (age and sex), clinical variables
(reason for OAT, INR range), and quality of the outcome (in terms of percentage of INR measurements in range
and complications) in both groups.
Results: Overall, 26.13 % of patients invited to participate in the intervention agreed. Of these, 99 % successfully
learned to self-manage their OAT. Just 4.2 % did not complete the follow-up, in all cases for reasons unrelated to
self-management, and 4.5 % required additional learning support. Outcomes were better than under usual care in
terms of percentage of INR measurements in range (12 %), rate of complications (4 %) and quality of life (9.2 %).
Limitations: Patients were only followed-up period for 6 months and the study was conducted in a single health
organization. Though patients eligible to participate were selected randomly, they were not randomly allocated to
the groups. This is a potential source of selection bias. Data needed to calculate in-range time were not collected
from controls; rather the results for the self-management group were compared with external data from other
studies.
(Continued on next page)
* Correspondence: tamayoedua@gmail.com
1Gros Health Centre, Donostia, Gipuzkoa, Spain
2Primary Care Research Unit-Gipuzkoa, Osakidetza, Spain
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tamayo Aguirre et al. BMC Cardiovascular Disorders  (2016) 16:180 
DOI 10.1186/s12872-016-0326-z
(Continued from previous page)
Conclusions: Almost all participants achieved competency in self-management, with no differences by age, sex,
concurrent illnesses, polypharmacy or educational level. The greatest barrier to self-management was the attitude
of patients themselves and those around them. Self-management in primary care is a good alternative to usual
care, patients having longer times in therapeutic range and fewer complications, and improving their quality of life.
Remote management is a good support tool.
Trial registration: ClinicalTrials.gov Identifier: NCT01878539.
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Background
Oral anticoagulant therapy (OAT) with vitamin K inhibi-
tors (acenocoumarol, warfarin) and rivaroxaban, apixaban
and dabigatran (new anticoagulant drugs) is a preventative
therapeutic measure for the treatment of cardiovascular
diseases, such as atrial fibrillation (the most common use),
valvular diseases and venous thromboembolic disorders.
Its use has progressively increased in recent years [1, 2]. In
our study, we only considered the first type, namely,
vitamin K inhibitors.
In the aforementioned cardiovascular diseases, there is a
high risk of thromboembolism and OAT has shown to be
effective in the prevention of associated complications,
although it also increases the risk of bleeding [3, 4]. Ap-
proximately 1.7–2 % of the Spanish population are on this
type of treatment, the figure reaching up to 9–10 % in
those over 65 years old, and increasing by 10 % per year
[5]. The mean age of the population continues to rise and,
with it, the prevalence of chronic illness; as a consequence,
haematology services are becoming overloaded and pri-
mary care providers have had to become involved in the
monitoring and follow-up of patients requiring OAT. The
efficacy of OAT is related to maintaining the patient
within a certain INR range (commonly between 2 and 3)
[6]. Often, however, the INR strays outside this range
(35–40 % of cases) [1–3, 5], and this is associated
with new cardiovascular events, such as thrombosis
due to low INR or bleeding due to high INR [3, 7, 8].
All the publications identified in the literature report
high percentages of INR measurements being outside
the target range, and hence, regular monitoring is ne-
cessary. This can be considered one of the weaknesses
of OAT [3, 6], and is associated with new cardiovas-
cular events, such as thrombosis due to low INR or
bleeding due to high INR [3, 7, 8].
In the optimisation of INR control, patients play an
essential role. For this reason, as in other chronic condi-
tions, studies have been conducted exploring INR control
with patient self-management [9, 10]. Self-testing is de-
fined as patients using the coagulometer and calculating
the INR themselves; they then submit the results to health
professionals, who decide on the appropriate regimen and
the date for the next check-up. Self-management is
patients adjusting the treatment themselves as a function
of their INR self-test results.
The efficacy of self-management of OAT has been
assessed in multiple clinical trials, and their results have
been synthesized in a systematic review [11]. This review
indicates that self-management patients obtain similar or
better results (data varying between authors) than patients
under usual care, those under self-management keeping
their INR in the therapeutic range for longer, and having
significantly lower rates of thromboembolic and haemor-
rhagic complications [12–14]. The associated increase in
the number of tests may also be a factor leading to better
outcomes (more frequent tests making it easier to identify
INR deviations early and promptly adjust medications,
increasing the time in-range) [15–17].
The studies included in the review excluded a variable
proportion of patients, due to clinical condition, age,
level of education, ability to learn and/or the opinion of
clinicians, with specific profiles emerging as a function
of age, functional and cognitive status and underlying
condition [11, 18]. These studies identify multiple advan-
tages of self-management including reductions in the
time dedicated to monitoring, both by clinicians and pa-
tients, in costs, and in the inconvenience associated with
regular testing; as well as improvements in quality of life
and satisfaction of patients [19].
When assessing the feasibility of introducing self-
management in routine practice in primary care, it is
first necessary to identify which patients are candidates
for this type of care and associated factors [20].
According to Jefferson Medical College (2005), potential
candidates are patients requiring long-term anticoagula-
tion therapy, who are highly motivated, and have suffi-
cient manual dexterity and vision [17]. Involvement and
education of patients in OAT, in terms of knowledge
of their condition and its treatment and management,
have been recognised as factors contributing to
achieving good outcomes using this treatment model
[3]. Further, the use of new information technologies
(Internet, e-mail, SMS) may favour patient self-
management [21], and this should be taken into
account. Self-management is not currently part of
routine practice with isolated exceptions.
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Taking into account the current situation, the objective
of this study was to explore factors related to self-testing
and self-management abilities of patients on OAT in pri-
mary care, as well as assess the quality of the outcome
achieved under this type of treatment [21, 22] and the
clinical consequences, comparing with usual care through
health centres and haematology services.
Methods
Study design
This was a multicentre prospective controlled quasi-
experimental study conducted between March 2012 and
November 2014 to identify factors associated with the
ability to self-manage and the clinical consequences of
self-management in OAT patients. The study protocol
was published by Tamayo-Aguirre et al. [22].
We included patients over 16 years of age on OAT
(for any reason) from seven different primary care health
centres in rural or urban settings of an integrated health-
care organisation (Donostialdea). The overall organisa-
tion had a catchment population of approximately
324,000, and 7,213 patients were on OAT (slightly over
2 % of the total population). We excluded patients with
serious diseases (hospitalised, or with a terminal diagno-
sis) and physically or mentally disabled individuals who
lacked adequate caregiving, as well as those who had
been on OAT for less than 1 year.
To estimate the appropriate sample size, we consid-
ered that for studies of predictive models, it has been
established at least 10 events of the dependent variable
of interest are needed for each independent variable in-
cluded in the multivariate logistic regression model [23,
24]. We estimated that we needed at least 100
dependent variable events. Previous studies [7, 12] indi-
cate that approximately 50 % is a “suitable” percentage,
and hence we would need 100 suitable and 100 non-
suitable candidates, yielding a total of 200 patients. In
the study published by Fitzmaurice et al. [10], 24 % of
patients declined to participate, 7 % did not attend study
meetings, 6 % did not sign the informed consent form,
and 3 % were excluded by researchers, amounting to a
40 % loss to follow-up. Assuming then that around 60 %
of patients agree to participate in this type of interven-
tion, if we wanted 200 participants in the intervention
group, we estimated we would need to recruit at least
333 patients for the initial sample, and for comparison,
the same number of controls.
Patient selection and recruitment
We spread awareness of the project among participating
organisations and members of staff potentially affected
were informed, with meetings in the form of clinical ses-
sions in health centres. Based on anonymised lists of
patients under active anticoagulant therapy at participating
centres, the coordinating research unit randomly selected a
sample of patients, who were then contacted by their
assigned primary care clinicians and invited to participate
in the study. Those who agreed to join the interven-
tion group were given a first appointment with a
member of the research team who provided them
with information regarding the study, requested their
written informed consent to participation in the
programme and allocated them to a training group.
Those who declined to participate in the intervention
were invited to participate as controls. They were
provided with information about the study, and asked
for oral consent, which was considered sufficient as
we only needed to access data from their records (no
intervention); further, we obtained approval from
Osakidetza to use data from the electronic health records.
Description of the intervention
We designed a bilingual (Spanish and Basque) training
programme focused on understanding and application of
self-management techniques. In this programme, partici-
pating individuals received training on OAT, self-testing
and self-management (Table 1). The training was based
on a programme developed in the regions of Aragón and
Catalonia, with written support materials (on a course of
oral anticoagulation) provided by Roche, and was
adapted to the needs of our study. It started with a
workshop in which specialised nurses provided theoret-
ical and practical information on OAT, and subse-
quently, four workshops were held with each patient
individually, in which he/she learned to use the Coagu-
Chek XS coagulometer, interpret INR results, adjust
doses and enter related data in the online monitoring
application (for more details, see Appendices I and II).
Study variables
The primary outcome variable was the capacity of
patients in the intervention group to self-manage. This
was assessed at the time of each INR measurement,
considering whether they had taken decisions following
the recommendations given (depending on the INR value
obtained, the recommendation was to repeat the measure-
ment, increase, maintain or decrease the dose, or contact
the doctor) and reported the test result (Appendix II).
This was based on the daily telemonitoring by the
clinician of the actions of the patient. Patients were
considered able to self-manage (positive outcome) if 95 %
of their actions were correct (according to the recommen-
dations given) and they committed no serious errors
(greater than 20 % deviation from the recommendations
as specified in Appendix II).
Patients were checked on every day through the web
service (97 %) or over the telephone (an option used by
3 % of patients), and at the end of the study period
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(6 months), data collected in the coagulometer were
retrieved and compared with those supplied directly by
the patients.
For all participants, we collected data on personal and
clinical characteristics, risk factors, all current medications
including anticoagulants, time on OAT, and recom-
mended INR range, as well as any vascular complications
that developed and INR control in terms of percentage of
INR measurements in range over the study period. In
intervention group patients, we also assessed time in
therapeutic range and quality of life (see below), compar-
ing baseline (when they had been under usual care) and
the period under self-management. These data were
collected either from the patient him/herself or from the
electronic health records of the Basque Health Service. In
addition, we collected basic information on individuals
who declined to participate (age, sex, current medications,
vascular complications and INR control).
Follow-up
Health records of control group patients were reviewed
at 6 months after their inclusion in the study. In the case
of intervention group patients, once we had checked the
ability of a patient to self-manage, he/she started to do
so and was then followed up for 6 months (i.e., from the
end of the training until the end of the study).
During the follow-up period (6 months), no meetings
were scheduled with these participants. To minimise
risks to patients and reassure researchers, data provided
by patients remotely (over the web or telephone) were
reviewed, and there were no cases in which their level of
control was sufficiently poor to indicate a need to inter-
vene. Given the possible need for support, two channels
of communication were provided:
1. Telephone: access to a 24/7 helpline to address both
technical and clinical queries
2. Internet: entering of self-management data (namely,
treatment variables, dose changes decided, any clinical
incidents occurred or other comments, and the date
of the next check-up) into a form on a website
(https://autocontrol.taonet.es/tao). The data on this
website was reviewed daily by a doctor, with the single
goal of assessing whether patients were at risk.
To assess the impact of the intervention in terms of
quality of life and patient satisfaction, we carried out a
survey based on the questionnaire of Sawicki [13]
designed to assess quality of life in OAT patients in
Germany, previously adapted to the Spanish setting by
Sánchez González [23] and used by Dávila Blazquez
[25]. The questionnaire consists of 32 questions grouped
to assess five parameters. Intervention group patients
were asked to complete questionnaires at baseline and
again at 6 months after the intervention.
Statistical analysis
On the one hand, we created a basic profile of patients
who declined to participate in the study with sex and
age data. On the other, for the intervention and control
groups, we considered a wider range of information:
reason for OAT, INR range, length of treatment, risks
factors, complications before and during the study,
polypharmacy, and whether they were independent for
activities of daily living or had a caregiver. Using this,
profiles of intervention and control patients were
created and compared, to determine whether they were
significantly different, using the Student’s t and the
chi-square tests for numerical and categorical variables,
respectively.
We then wanted to assess the results of self-management
compared to usual care through health centres and haema-
tology units, and for this, we analysed outcomes as a
function of case/control status. Specifically, we analysed the
time in therapeutic range, percentage of in-range measure-
ments, and clinical complications. We also explored pre- to
post-intervention changes in quality of life in the interven-
tion group.
To calculate the percentage of time in days when the
INR was in the therapeutic range, we used the Rosendaal
test (considering a value <60 % to indicate poor control,
based on [26]). Further, we calculated the percentage of
INR measurements in range during the 6 months prior
to the study and the 6 months of the study, for both
intervention and control groups.
The frequency of testing differed between the groups.
Patients in the control group continued to be tested at
the usual frequency, as scheduled with their usual doc-
tor, while patients in the intervention group (under self-
management) were scheduled to self-test every 7 days, in
line with the pattern in previous similar studies. The test
results of the self-management group were reviewed by
a doctor, but no intervention was performed. In the case
of controls, their nurse conducted the tests, and their
doctor reviewed the results and prescribed their
treatment.
We designed a relational database using Microsoft
Access 2010 for all the study data. The descriptive and
statistical analysis was carried out using R software ver-
sion 3.1.2 [27].
Results
The study was conducted in the Donostialdea Integrated
Healthcare Organisation, which has 21 health centres,
with a total of 7,212 patients on OAT (Fig. 1). We se-
lected seven centres with different characteristics in
terms of size, and urban or rural settings, among other
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factors, leaving a target population of 2,548 patients.
The number of patients initially selected from each
centre was proportional the total eligible population at
the centre.
To achieve the desired sample size for the intervention
group, we contacted 1,274 patients (50 % of the selected
target population), and 442 (35 %) meet selection criteria
and agreed to participate in the intervention (Fig. 1). Of
this group (n = 442) that started the study, 101 patients
(22.85 %) did not complete the training process: 42 did
not attend the first meeting, while 36 withdrew after the
first workshop, 20 after the second workshop and 3 just
before the end. Out of the 341 patients who completed
the training programme, 8 (2.3 %) were not included in
the analysis as they had moved into residential care,
although they did not have any problems in terms of
participation.
Finally, 333 intervention group patients were included in
the analysis (26.13 % of those initially contacted). Out of
the 832 individuals that did not take part in the interven-
tion, 367 (29.51 %) declined to participate, 379 (29.74 %)
did not met the selection criteria, and 86 (6.75 %) were
unable to participate (due to treatment cessation or
changes, hospitalisation, pre-surgical admission, moving
away from the area or being regularly away, or monitoring
in other centres).
There were no significant differences in participa-
tion rate by time on OAT, risk factors, the presence
of polypharmacy, or whether patients required a care-
giver. All 333 patients invited to join the control
group agreed.
Patient characteristics
Among the intervention group participants, 65.5 %
were men and the mean age was 73.5 years (Table 2).
The recommended INR range was 2.0-3.0 in most
cases (79 %), being somewhat higher (2.5-3.5) in the
others. The mean reason for OAT was heart
arrhythmia due to atrial fibrillation followed by aor-
tic valve prosthesis. Regarding length of treatment,
most participants had been on OAT for 4 years or
more. Around two-thirds of participants were
independent, a third required a caregiver, and 10.5 %
required home care. The most common risk factors
identified were hypertension, hyperlipaemia and
diabetes.
Comparing the groups, which were the same size, the
controls were somewhat older (mean of 4.2 years) and
there was a higher percentage of men (65.5 %) in the
intervention group, while the gender distribution was
balanced in the control group. Other differences were
the distribution of the patients in terms of the number
Fig. 1 Flow of patients through the study
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Table 1 Timetable and content of the training
Workshop Duration Type Number of patients Content
1 1 h group/individual 2 OAT, starting self-management
2 1 h individual 1 Coagulometer, tables, Internet
3 30 min individual 1 Checking, clarification, survey
4 30 min individual 1 Data entry, starting point
5 1 h Individual 1 End of study, survey
Table 2 Summary of patient characteristics at baseline
Usual monitoring Self- management p-value
Patients, n 333 333
Sex, n (%) Male 160 (48.0) 218 (65.5) p < 0.0001
Female 173 (52.0) 115 (34.5)
Age, mean (SD) Male 75.7 (9.2) 69.5 (11.9) p < 0.0001
Female 77.7 (8.5) 73.5 (13.8)
Reason for OAT, n (%) Heart arrhythmia due to atrial fibrillation 242 (72.7) 221 (66.4) 0.051
Aortic prosthesis 24 (7.2) 43 (12.9)
Deep vein thrombosis 15 (4.5) 23 (6.9)
Mitral valve prosthesis 17 (5.1) 17 (5.1)
Pulmonary thromboembolism 21 (6.3) 10 (3.0)
Cerebrovascular accident 7 (2.1) 5 (1.5)
Deficit proteins 0 (0.0) 4 (1.2)
Others 3 (0.9) 4 (1.2)
Valvular heart disease 3 (0.9) 4 (1.2)
Ischemic heart disease 1 (0.3) 2 (0.6)
INR ranges n (%) 1.5–2.5 0 (0.0) 1 (0.3) 0.029
2.0–3.0 287 (86.2) 264 (79.3)
2.5–3.5 46 (13.8) 68 (20.4)
Length of treatment, 1–3 96 (29.0) 85 (25.7) 0.77
years (%) 4–7 105 (31.7) 106 (32.0)
8–10 52 (15.7) 54 (16.3)
>10 78 (23.6) 86 (26.0)
Risk factors, Arterial hypertension 217 (37.8) 196 (37.9) 0.132
n (%) Diabetes mellitus 85 (14.8) 69 (14.4)
Hyperlipaemia 169 (29.5) 180 (34.1)
Cancer 50 (9.2) 35 (6.8)
Liver disease 6 (1.3) 14 (1.5)
Kidney disease 40 (7.4) 32 (5.3)
Polypharmacy, n (%) 1–3 drugs 70 (21.3) 102 (39.5) p < 0.0001
4–7 drugs 139 (42.6) 156 (37.2)
8–12 drugs 108 (30.9) 59 (19.8)
13 or more drugs 16 (5.1) 16 (3.5)
Other, Independent 226 (67.9) 219 (65.8) 0.621
n (%) Caregiver 107 (32.1) 114 (34.2)
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of drugs taken, though all patients in both groups were
taking multiple medications, and that more patients
under self-management than controls had a slightly
higher recommended INR range (2.5–3.5). On the other
hand, there were no significant differences between
groups in time on OAT, reason for OAT, risk factors, or
independence/reliance on a caregiver.
Intervention group training
Out of the 333 patients included in the self-
management intervention, 14 (4.20 %) despite having
completed the training successfully did not complete
the follow-up for various reasons unrelated to the
self-monitoring, such as death, changes in treatment
and moving away. Of those who completed the inter-
vention, 16 (4.80 %) found difficulties in learning the
knowledge/skills taught in the training programme
and required extra support to complete it. Only one
person did not achieve the proposed learning
objectives.
Overall, nearly all (99.69 %) of the intervention group
patients who completed the training and follow-up were
considered to be competent in self-management, on the
basis that as well as having met the learning objectives
of the programme, they met the following criteria: good
handling of the coagulometer, lancet, and test strips;
good interpretation of results; appropriate decisions on
treatment adjustment on more than 95 % of occasions;
and correct data entry. Given the negligible proportion
of patients not considered to be competent (1 case), we
did not carry out a comparative analysis.
INR control
The mean in-range time in the intervention group (74.4
%) was notably higher than that in controls from other
studies (58,6 %) [21]. The mean difference score between
the control group and the study measurements was 15,8
% (95 % confidence interval: 5.67, p < 0,001).
Over the 6 month study period, the intervention
group patients performed 26 INR self-tests and con-
trol group patients had 14 tests conducted by
clinicians.
Considering the raw data, INR measurements in
controls were in range in 63 % of tests, results being 12
% better in the intervention group (75 %; p < 0.0001).
Further, analysing the individual INR data for each
patient, results were similar, 34 % and 24 % of INR
measurements being out of range in controls and
intervention group patients respectively (p < 0.0001).
Analysing the individual percentages of in-range
measurements for all patients (Table 3), 58.26 % of
patients under usual care and 88.89 % of patients
under self-management can be considered to have
achieved good INR control (indicated by more than
60 % of measurements lying within range).
Clinical complications
During the study period, the rate of severe haemorrhage
was somewhat higher in the usual care than in the self-
management group, and the same was true for acute myo-
cardial infarction, mild haemorrhage, thromboembolism
and death; though the differences did not reach significance
(Table 4).
Quality of life
The quality of life questionnaire administered before
and after the intervention was used to explore
changes following the initiation of self-management.
Pre-intervention results were comparable with those
of Blazquez et al. [25]. A total of 415 questionnaires
were received from self-management patients, 196 at
Table 3 Percentage of INR measurements within the range
% in-range for
each patient
Patients under
usual monitoring
% Patients under
self-management
%
<50 % 61 18.32 8 2.40
50–55 % 41 12.31 13 3.90
56–60 % 37 11.11 16 4.80
61–65 % 18 5.41 28 8.41
66–70 % 34 10.21 42 12.61
71–75 % 38 11.41 46 13.81
76–80 % 16 4.80 52 15.62
>80 % 88 26.43 128 38.44
Table 4 Results of the questionnaires
Item Baseline 6 months % p-value
General treatment dissatisfaction 2.27 2.03 −10.57 <0.001
Self-efficacy (in disease management) 4.51 4.93 +9.31 <0.001
Strained social network (psychological stress) 3.17 2.87 −9.46 <0.001
Daily hassles 2.14 1.94 −9.34 0.017
Distress (in social situations) 1.78 1.65 −7.30 0.019
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baseline (58.85 %) and 219 (65.76 %) at the end of
the intervention, and the results indicated significant
improvements in quality of life.
Discussion
This study was conceived from a primary care setting
to analyse the ability of patients on OAT to self-test
and self-manage, as well as assess the clinical impact
of this approach, in terms of the control of their
treatment and complications.
1. Almost all patients (99.7 %) who participated in the
self-management programme were considered to
have acquired the target knowledge/skills. This study
demonstrates that patients who attend and complete
a self-management programme are successfully able
to self-manage, as has been found by other authors,
though success rates vary (e.g., Fitzmaurice et al.
[10] and De Felipe et al. [28] reporting rates of
57 and 100 % respectively). In our study, 16 patients
(4.80 %) found it more difficult than had been
expected to achieve the learning objectives,
but succeeded with just two additional sessions.
Menéndez-Jándula et al. [17] found a considerably
higher rate (13 %) of patients requiring extra
support. Cayley, WE Jr [18] indicated that between
25 and 90 % of patients may be able to self-test
and self-manage, but they did not analyse the
underlying reasons; that is, the authors mention
some possible barriers but do not assess their
relative importance.
In our study, the main barrier to self-management
was related to reluctance of patients to participate,
this contributing to reduce the sample analysed
to 26.13 % of those contacted. Other researchers
have mentioned this issue but did not quantify
the extent of the problem [11]. Overall, therefore,
nearly three-quarters (73.87 %) of patients we
contacted were not finally included in analysis
of the self-management programme, in most cases
for personal reasons, reasons given by caregivers or
health professionals, or other non-modifiable
factors such as hospitalisation, discontinuation
of or changes in treatment, moving away or
monitoring in other centres. Similar factors have
been identified in some other studies [11, 18].
Other authors mention a different range of factors
that hinder follow-up of participants, including
patient age, medical condition, skills, level of
education, willingness, social level, and clinical
events, as well as the influence of health
professionals [11, 17, 29].
In our case, the rate of withdrawal during the
training period was 23 % of those who initially
attended. As reported by other researchers,
withdrawal by this type of patients is relatively
common, ranging from 17 to 33 % [17].
2. 2. Notably, 96 % of those initially included in
the intervention group achieved good self-
management during the 6-month study period
(in terms of INR measurements, treatment
adjustment, and data entry in more than
95 % of the measurements). Only 14 patients
(4.20 %) were lost to follow-up, but this was
for reasons unrelated to self-management,
compared to a figure of 21 % in the study of
Menéndez-Jándula et al. [17].
3. 3. Like in previous research [18], in our study,
age was not a determinant factor, though self-
management patients were a mean of 4 years
younger than the controls. Further, in the self-
management group, more than half of participants
were men (65.5 %), but no differences were
observed between groups as a function of
aetiology, concurrent illnesses or mental or
physical ability [21].
4. 4. Self-management may be considered an
acceptable option if we obtain similar results to
those obtained with usual care. In fact, comparing
data with those monitored through haematology
services and health centres, our self-management
patients obtained better INR control (in terms
of both percentage of in-range measurements
compared to controls and time in-range compared
to usual values). Over the last 15 years, there have
been a growing number of studies involving patients
self-managing OAT [4, 5, 7, 10, 11, 15–18, 30],
several authors reporting similar results to ours
[4, 8, 10, 31].
5. 5. Moreover, we found lower rates of clinical
complications (serious or mild), deaths, and
admissions and a better clinical course in
patients under self-management, confirming ob-
servations of Heneghan et al. [29] and
Bloomfield et al. [32]. Analysing the types
of complications, we observed that many of
them occurred concurrent with other health
problems (rectorrhagia with intestinal lesions
and haemorrhoids, haematuria with prostate,
kidney or bladder cancer, metrorrhagia with
cervical or womb cancer), and we propose that
these should be the focus of separate research.
On the other hand, some other types of
bleeding such as epistaxis, gum bleeding,
and microhaematuria may be more closely
related to OAT, since they did not occur
together with other aetiologies. We have
not, however, quantified these data.
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6. 6. In our study, self-management patients
reported high levels of personal satisfaction,
as reflected in the quality of life results
(Table 5), confirming the observations of
other authors [11, 17, 29, 33]. There is
growing evidence that self-management is
not just another option, rather it is a
system that actually improves outcomes
in patients, in terms of INR control,
clinical complications, and quality of life
[11, 17, 29]. We have not conducted
cost analysis, but plan to do so in the
near future.
7. 7. Remote monitoring of patients was key to
the study, given that self-management carries
a certain level of risk for patients but with
telemonitoring this risk could be managed.
Notably, telemonitoring was only used for
checking progress and was not interventionist
in nature.
Patients were asked to use a website to submit
data about their measurements, the decisions they
took depending on their results, and any clinical
events. A total of 93 % managed to use the website
(by themselves, or with help, from relatives, friends,
caregivers, or a community centre, among other strat-
egies), the remaining patients reporting their data by
phone.
Researchers reviewed the data submitted by pa-
tients every day and noted the actions taken follow-
ing each test, to assess the quality of self-
management and detect any possible erroneous ac-
tions that could pose a risk to the patient’s health.
Patients were contacted to resolve concerns in rela-
tion to 2 % of measurements, but in no cases was it
considered necessary to intervene or modify the ac-
tions taken by patients.
The 24-h telephone helpline was maintained
throughout the follow-up period, to resolve clinical
or technical concerns. It was used a mean of 0.6
times per patient during the 6 month period. Of
the total of 76 calls received, 32 (42 %) were related
to administrative issues and 25 (32.9 %) to technical
problems, while 19 concerned self-management it-
self, all of these calls occurring in the first month
of the study.
These channels of communication with patients
during the study period were found to be useful, the
web data making it possible to immediately assess
patients’ actions to avoid serious risks, while clinical
and technical problems were resolved over the tele-
phone, and though there were relatively few such
problems, the helpline strengthened patients’ confi-
dence. These resources have been important to safe-
guard patient safety while avoiding regular contact
between researchers and patients that would otherwise
have been necessary.
We have found no other studies that have employed
such an approach. Telemonitoring has tended to be
used as a tool for doctor-patient communication but
not for self-managed patients. We believe that these
two channels of communication combined make a
great tool, both highly practical and feasible, and that
their use could be widened to monitoring of patients
with other chronic illnesses.
There was also good participation from health
professionals, doctors and nurses at the health cen-
tres, despite the fact that at the outset we thought
this might have been a weak point of the study.
Their support was very valuable. We consider that
the information they were given about the study,
their supervision, the initial clinical session and
open channels of communication were essential for
the positive attitudes shown. A possible future line
of research would be to explore strategies for
changing attitudes of patients, caregivers and health
professionals [19], in order to assess the possibility
of increasing the number of patients under this
type of care. Further, there is a need for more re-
search to establish the relationship between OAT
and various types of complications, analysing their
causes.
Strengths of the study
This was a randomised multicentre study con-
ducted in primary care with no limits on age, med-
ical condition, mental or physical status, drawing
patients from small, medium and large health
centres in rural and urban settings, with no condi-
tioning economic factors and with support from the
Carlos III Health Institute, Osakidetza, and Roche.
Table 5 Percentage of time in therapeutic INR range in patients
under self-management
Percentage of time in-range
for each patient
Patients under
self-management
%
<50 % 31 9.31
50–55 % 26 7.81
56–60 % 36 10.81
61–65 % 30 9.01
66–70 % 45 13.51
71–75 % 39 11.71
76–80 % 41 12.31
>80 % 85 25.53
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Weaknesses
Patients were recruited progressively and hence the
training was not carried out at the same time for all
participants and the data for controls was collected
over a different time period. Further, given the design
of the sample, the intervention group only contained
individuals who wanted to participate.
Conclusions
Patients who are fit and willing and/or who have a
suitable and willing caregiver are able to self-manage
OAT, regardless of age, reason for the OAT, and the
presence of multimorbidity, polypharmacy or other
risk factors. Our results underline the potential of
self-management across the full spectrum of patients,
those under this type of management not only match-
ing but improving on the level of INR control
achieved under usual care.
The results obtained in this study demonstrate the
ability of motivated patients to self-manage, levels of
control being not only as good as but even better
than those receiving usual care. Self-management is
also associated with an improvement in patient
quality of life. The fact that self-management im-
proves control and other outcomes in patients on
OAT should strengthen our interest in the use of
this approach in other chronic illnesses. A possible
future avenue of research would be to explore ways
of changing attitudes in patients, caregivers and cli-
nicians [18] seeking to increase the proportion of
patients who engage in self-management. Further
research is also required into the economic and
organisational impact of self-management on health
services.
Appendix I
Training
First workshop: In a session lasting 1 h, groups of
four people were provided with information and
training related to the characteristics of their condi-
tion and treatment. At the end of the session, every
patient was requested to sign an informed consent
form. Those who agreed continued in the study,
while those who declined were replaced by other
patients.
Second workshop: Held the following day and also
lasting 1 h, this session focused on the use of the
coagulometer (device for determining INR) and use
the tables for self-adjusting their treatment. They
were also taught how to enter their data into a form
on a website, allowing healthcare professionals leading
the study to monitor their progress. They were re-
quested to complete a questionnaire on the quality of
life of patients on OAT.
In this workshop, patients practiced what they would
have to do later by themselves:
handling of the coagulometer, completion of INR
measurements, simulation of dose adjustment, and
data entry on the website: https://autocontrol.tao-
net.es/tao.
Patients, with a username and password, were able
to access their data and enter data on the results and
observations every time they measured their INR. The
principal investigator of the project accessed the data
entered by all the patients every day, to check on the
progress of the self-management of each patient,
assessing both the INR data and the clinical notes of
patients, aiming to avoid serious errors in the
process.
Third workshop: This was held 1 week after the first
workshop. Patients carried out the test in their own
homes and then attended the workshop. Patients’
learning was checked and the content of previous
sessions was reviewed. Any remaining doubts were
addressed.
If patients were considered to have met the
learning objectives (successfully using the coagul-
ometer, obtaining a drop of blood, applying the
tables, and communicating the results), they were
provided with all the materials necessary for per-
forming self-testing over the 6-month study period
and were given an appointment for 3 weeks later.
If not, they were given extra sessions, after which
those considered ready for self-management were
provided with the aforementioned materials and
given an follow-up appointment at 3 weeks. If we
considered that patients had not learned enough,
even with extra support, agreement was reached
that they would not participate in the study.
Fourth workshop: At 1 month after the first work-
shop, we checked what patients had done during
the month of self-management, and INR measure-
ments taken using the coagulometer data were
downloaded. We addressed any remaining problems
or queries and finally certified that they had com-
pleted the training satisfactorily.
Fifth workshop: After 6 months, patients were
contacted by phone to arrange a final session. We
collected the data from the coagulometer and
transferred them to the computer software, cross-
checking with the data submitted by patients
themselves.
Lastly, patients were requested to complete the ques-
tionnaire on the quality of life of patients on OAT for a
second time. We thanked patients for their participation,
giving them a diploma and declaring that the study had
been completed.
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Appendix 2
Abbreviations
INR: International normalized ratio; OAT: Oral anticoagulation therapy.
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Summary
Oral anticoagulation therapy can be self-managed by 99 % of patients and
their caregivers if they are provided with adequate training and monitored.
The main barrier to self-management is the willingness of patients and/or
caregivers themselves. When achieved, self-management improves INR
control, increases the time in therapeutic range, and reduces complications
and mortality, while also improving patient quality of life.
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